Choosing a Behavioral Therapy Platform for Pharmacotherapy of Substance Users

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2004 Jul 28

PMID 15276217

Citations 37

Authors

Kathleen M Carroll

Thomas R Kosten

Bruce J Rounsaville

Affiliations

Soon will be listed here.

Abstract

Behavioral therapy platforms have become virtual requirements in pharmacotherapy trials due to their utility in reducing noise variability, preventing differential medication adherence and protocol attrition, enhancing statistical power and addressing ethical issues in placebo-controlled trials. Selecting an appropriate behavioral platform for a particular trial requires study-specific tailoring, taking into account both the stage of development of the medication being evaluated, as well as the specific strengths and weaknesses of a broad array of available empirically supported behavioral therapies and the range of their possible targets (e.g., enhancing medication adherence, preventing attrition, addressing co-morbid problems, fostering abstinence, and targeting specific weaknesses of the pharmacologic agent). Choosing a suitable behavioral platform also requires consideration of the characteristics of the population to be treated, stage of scientific knowledge regarding the medication's effects, appropriate balance of internal and external validity, and consideration of potential ceiling effects. Available manualized behavioral treatments are reviewed, noting their strengths and limitations as behavioral therapy platforms for pharmacotherapy trials and as potential concomitant therapies in clinical practice.

Citing Articles

Contingency Management for Treatment of Cannabis Use Disorder in Co-Occurring Mental Health Disorders: A Systematic Review.

Rodas J, Sorkhou M, George T Brain Sci. 2023; 13(1).

PMID: 36672017 PMC: 9855987. DOI: 10.3390/brainsci13010036.

Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial.

Schmitz J, Lane S, Weaver M, Narayana P, Hasan K, Russell D Contemp Clin Trials. 2021; 111:106603.

PMID: 34688917 PMC: 8678331. DOI: 10.1016/j.cct.2021.106603.

N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial.

Back S, Gray K, Ana E, Jones J, Jarnecke A, Joseph J Contemp Clin Trials. 2020; 91:105961.

PMID: 32087337 PMC: 7333883. DOI: 10.1016/j.cct.2020.105961.

Computerized Cognitive Behavioral Therapy for Substance Use Disorders: A Summary of the Evidence and Potential Mechanisms of Behavior Change.

Kiluk B Perspect Behav Sci. 2020; 42(3):465-478.

PMID: 31976445 PMC: 6768920. DOI: 10.1007/s40614-019-00205-2.

Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again.

Carroll K, Kiluk B Psychol Addict Behav. 2017; 31(8):847-861.

PMID: 28857574 PMC: 5714654. DOI: 10.1037/adb0000311.

References

Freedman B . Equipoise and the ethics of clinical research. N Engl J Med. 1987; 317(3):141-5. DOI: 10.1056/NEJM198707163170304. View

Seal K, Kral A, Lorvick J, McNees A, Gee L, Edlin B . A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend. 2003; 71(2):127-31. DOI: 10.1016/s0376-8716(03)00074-7. View

DeRubeis R, Crits-Christoph P . Empirically supported individual and group psychological treatments for adult mental disorders. J Consult Clin Psychol. 1998; 66(1):37-52. DOI: 10.1037//0022-006x.66.1.37. View

. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997; 58(1):7-29. View

Silva de Lima M, Soares B, Reisser A, Farrell M . Pharmacological treatment of cocaine dependence: a systematic review. Addiction. 2002; 97(8):931-49. DOI: 10.1046/j.1360-0443.2002.00209.x. View

Dunn C, Deroo L, Rivara F . The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. Addiction. 2002; 96(12):1725-42. DOI: 10.1046/j.1360-0443.2001.961217253.x. View

Lavori P . Clinical trials in psychiatry: should protocol deviation censor patient data?. Neuropsychopharmacology. 1992; 6(1):39-48; discussion 49-63. View

Griffith J, Roark R, SIMPSON D . Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000; 58(1-2):55-66. DOI: 10.1016/s0376-8716(99)00068-x. View

Miller F . Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry. 2000; 47(8):707-16. DOI: 10.1016/s0006-3223(00)00833-7. View

10.

Modesto-Lowe V, Van Kirk J . Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol. 2002; 10(3):213-27. DOI: 10.1037//1064-1297.10.3.213. View

11.

Little K, Zhang L, Desmond T, Frey K, Dalack G, Cassin B . Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry. 1999; 156(2):238-45. DOI: 10.1176/ajp.156.2.238. View

12.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L . Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry. 1999; 56(6):493-502. DOI: 10.1001/archpsyc.56.6.493. View

13.

Morgenstern J, Morgan T, McCrady B, Keller D, Carroll K . Manual-guided cognitive-behavioral therapy training: a promising method for disseminating empirically supported substance abuse treatments to the practice community. Psychol Addict Behav. 2001; 15(2):83-8. View

14.

Kosten T, Rosen M, Bond J, Settles M, St Clair Roberts J, Shields J . Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 2002; 20(7-8):1196-204. DOI: 10.1016/s0264-410x(01)00425-x. View

15.

Allen J, Litten R . Techniques to enhance compliance with disulfiram. Alcohol Clin Exp Res. 1992; 16(6):1035-41. DOI: 10.1111/j.1530-0277.1992.tb00695.x. View

16.

Hall S, Humfleet G, Reus V, Munoz R, Hartz D, Maude-Griffin R . Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry. 2002; 59(10):930-6. DOI: 10.1001/archpsyc.59.10.930. View

17.

Bien T, Miller W, Tonigan J . Brief interventions for alcohol problems: a review. Addiction. 1993; 88(3):315-35. DOI: 10.1111/j.1360-0443.1993.tb00820.x. View

18.

Carroll K, Rounsaville B, Gordon L, Nich C, Jatlow P, Bisighini R . Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994; 51(3):177-87. DOI: 10.1001/archpsyc.1994.03950030013002. View

19.

Fals-Stewart W, OFarrell T, Birchler G . Behavioral couples therapy for male substance-abusing patients: a cost outcomes analysis. J Consult Clin Psychol. 1997; 65(5):789-802. DOI: 10.1037//0022-006x.65.5.789. View

20.

Higgins S, Delaney D, Budney A, Bickel W, Hughes J, Foerg F . A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991; 148(9):1218-24. DOI: 10.1176/ajp.148.9.1218. View